Date | Price Target | Rating | Analyst |
---|---|---|---|
9/16/2024 | $57.00 | Buy | Jefferies |
9/4/2024 | $55.00 | Outperform | Bernstein |
7/24/2024 | $58.00 | Overweight | Morgan Stanley |
2/16/2024 | $62.00 | Outperform | RBC Capital Mkts |
2/6/2024 | $59.00 | Buy | UBS |
12/22/2023 | $50.00 | Buy | H.C. Wainwright |
12/8/2023 | $58.00 | Outperform | Robert W. Baird |
1/24/2023 | $24.00 | Outperform | SVB Securities |
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price Target of $58.
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Biohaven The Trade: Biohaven Ltd. (NYSE:BHVN) Director John W Childs acquired a total of 28,400 shares at an average price of
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
8-K - Biohaven Ltd. (0001935979) (Filer)
424B7 - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300:The Company reported dose-dependent and rapid IgG reductions in its ongoing Phase 1 trial with its lead investigational degrader BHV-1300No serious adverse events (SAEs) reported with BHV-1300 to date; most adverse events (AEs) were mild, deemed unrelated to study drug and resolved spontaneouslyPhase 1 study also completed an assessment of an optimized subcutaneous (
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platformBHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administrationNo SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneouslyNo clinically significant changes in LFTs across any dose cohorts to dateHighlights advances from novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain and neuropsychiatric disease indicationsRecently initiated a total of 5 pivotal clinical trials with selective Kv7 ac
Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00
Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00
Morgan Stanley initiated coverage of Biohaven with a rating of Overweight and set a new price target of $58.00
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi
NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy. Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. K
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was
Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally Full-Year 2022 Reported Diluted EPS(2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS(3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer Fourth-Quarter 2022 Reported Diluted EPS(2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS(3) of $1.14, Up 45% Year-Over-Y
Solid Third-Quarter 2022 Revenues of $22.6 Billion Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Third-Quarter 2022 Reported Diluted EPS(2) of $1.51, Reflecting 6% Growth Over Third-Quarter 2021, Including a $0.15 Incremental Benefit in the Current Period Related to Tax Resolutions for Multiple Years Impacting Both Reported(2) and Adjusted(3) Diluted EPS Third-Quarter 2022 Adjusted Diluted EPS(3) of $1.78, Reflecting 40% Growth Over Third-Quarter 2021; Excluding Foreign Exchange Impacts, Adjusted Diluted EPS(3) Grew 44% Raises Lower